Fetal AnemiaNCT07409961
Middle Cerebral Artery Acceleration Time as Indicator in Fetal Anemia
An observational study of Fetal Anemia, run by Assiut University.
Trial summary
Fetal anemia one of serious fetal problems that may lead in sever cases to fetal demise early detection and precise intervention safe fetal life , traditional evaluation the severity and need of blood transfusion done by middle cerebral artery peak systolic velocity in doppler wave, in this study innovative technique… Read more about this study
- Who is it for?
- Ages 18 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Fetal Anemia
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- 1 Mar 2026to 1 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: pregnant women with fetus complaining hyperdynamic state or fetal anemia
Who may be able to join
- fetus with fetal anemia or hyperdynamic state
Who cannot join
- associated fetal congenital anomalies
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Fetal anemia one of serious fetal problems that may lead in sever cases to fetal demise early detection and precise intervention safe fetal life , traditional evaluation the severity and need of blood transfusion done by middle cerebral artery peak systolic velocity in doppler wave, in this study innovative technique suggested to compared with standard technique
- Conditions
- Fetal Anemia
What is being measured
The primary outcome is the main question the study is designed to answer.
acceleration time in middle cerebral artery doppler
time in millisecond in middle cerebral artery waveform from beginning of systole to reaching peak velocity
Measured: 5 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2026
- Study start1 Mar 2026 (estimated)
- Primary completion1 Mar 2027 (estimated)
- Study completion1 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Fetal AnemiaStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case crossover
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sief el eslam Ahmed Ali, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07409961
- Sponsor's protocol ID
- AUOBG052026
- Status last verified
- Feb 2026
- First submitted
- 7 Feb 2026
- Last updated
- 13 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Middle Cerebral Artery Acceleration Time as Indicator in Fetal Anemia
- ClinicalTrials.gov ID
- NCT07409961
- Acronym / sponsor ID
- AUOBG052026
- Conditions
- Fetal Anemia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- 1 Mar 2027 (estimated)
- Study completion
- 1 Jun 2027 (estimated)
- First posted
- 13 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fetal anemia one of serious fetal problems that may lead in sever cases to fetal demise early detection and precise intervention safe fetal life , traditional evaluation the severity and need of blood transfusion done by middle cerebral artery peak systolic velocity in doppler wave, in this study innovative technique suggested to compared with standard technique
Study design
- Observational model
- Case crossover
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- pregnant women with fetus complaining hyperdynamic state or fetal anemia
Key inclusion criteria (1 listed)
- fetus with fetal anemia or hyperdynamic state
Key exclusion criteria (1 listed)
- associated fetal congenital anomalies
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
acceleration time in middle cerebral artery doppler
Time frame: 5 minutes
time in millisecond in middle cerebral artery waveform from beginning of systole to reaching peak velocity
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
Related trials for Fetal Anemia
RecruitingObservational study
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
RecruitingPhase 2
Neonatal Outcomes on Direct Fetal Intravenous Immunoglobulin During Intrauterine Transfusion for Rhesus Isoimmunization
Hemolytic Disease of the Newborn, Fetal Anemia
Active, not recruitingPhase 2
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)
Sickle Cell Disease
RecruitingObservational study
Transfusion-Related Changes in Oxidative Stress Biomarkers in Neonates
Oxidative Stress in Neonates, Near Infrared Spectroscopy
Not yet recruiting
MoDi Twin Placental Imaging
Monochorionic Diamniotic Placenta, Monochorial Monoamniotic Placenta
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Fetal Anemia, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sief Ali (01004971596, siefali-2020@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
acceleration time in middle cerebral artery doppler (time frame: 5 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.